UP-TO-DATE, RESEARCH BASED INFORMATION ABOUT PSYCHEDELICS.
Cognitive behavioral therapy, ketamine, and combination treatment for depression: Impressions of credibility in participants with self-reported depressive symptoms
Additional research on individual differences in perceptions of ketamine and varied treatments for depression seems warranted.
Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges
There were no serious AEs related to psilocybin and LSD administration. Most AEs were expected, manageable and transient.
Psychedelic experiences and mindfulness are associated with improved wellbeing
These data are among the first to establish a strong relationship between personal mindfulness practice, recreational psychedelic use, and overall psychological wellbeing in a naturalistic framework
Differences in personality, cognitive abilities, illicit drug use, and white matter structural integrity between hallucinogen users and matched controls
These findings are consistent with reports that hallucinogen use may lead to shifts in personality as well as multiple cognitive domains.
The therapeutic potential of psychedelic-assisted therapies for symptom control in patients diagnosed with serious illness: A systematic review
The evaluated evidence suggests positive effects of psychedelic-assisted therapies for symptom control in patients diagnosed with serious illness.
Hallucinogen persisting perceptual disorder: a scoping review covering frequency, risk factors, prevention and treatment
The renewed interest in psychedelics for select mental disorders ... provides the impetus to characterize HPPD in its frequency, risk and protective factors, key characteristics ...
Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms
The results confirm psilocybin mushrooms are a relatively safe drug, with serious incidents rare and short lasting.
Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample
Lifetime psilocybin use was associated with lowered odds of OUD.
Therapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression
Future research should ... consider how therapeutic approaches might adapt in cases of weaker therapeutic alliance.
Counselors’ attitudes (in USA) toward psychedelics and their use in therapy
Most counselors see potential in PAT and the need for additional research.
Predictors and potentiators of psychedelic-occasioned mystical experiences
This review examines these factors and considers how they might be optimised to increase the chances of a mystical experience occurring.
Virtual reality as a moderator of psychedelic-assisted psychotherapy
We conclude that the potential application of VR in modulating psychedelic-assisted psychotherapy demands further exploration and an evidence-based approach to both design and implementation.
A single belief-changing psychedelic experience Is associated with increased attribution of consciousness to living and non-living entities
This study demonstrates that, among people who reported belief-changing psychedelic experiences, attribution of consciousness to various entities increases.
Trips and neurotransmitters: Discovering principled patterns across 6850 hallucinogenic experiences
Natural language–processing tools mine 6850 real-world narratives about 27 different psychedelic drugs.
Psilocybin-assisted Compassion Focused Therapy for depression
In this paper, we describe the rationale for selecting CFT, the compatibility of CFT and psilocybin-therapy, an overview of the psilocybin-assisted CFT protocol, the study protocol.
Psychedelic medicine: A review of clinical research
We believe this is the most comprehensive summary of research on psychedelics as a class that currently exists.